Commercial-scale viral vector manufacture: Technical challenges & strategic implications

In by

February 14th 2018; 08:00 PST; 11:00 EST; 16:00 GMT; 17:00 CET

Sponsored by:
Pall LifeScience

Following recent mainstream media coverage of reported supply and demand mismatch, viral vectors now dominate much of the discussion within the cell and gene therapy sector. This panel webinar will provide insight from three leading experts at the forefront of vector manufacturing, as they share their first-hand experiences in moving to commercial-scale manufacture of viral vectors including:

  • Current approaches to commercial-scale manufacture of viral vectors and the unique challenges/limitations of each.
  • Real world experience of the different upstream and downstream processes and their impact on yield, efficiency, safety, cost of goods.
  • Potential impact of vector manufacturing decisions on your business model and clinical development timeline.

Throughout the webinar, you will have the opportunity to pose your questions to our speakers:

  • Dr Michael Kelly, Director, Asset Leadership, Gene Therapy, Biogen
  • Dr Clive Glover, Senior Global Marketing Manager, Cell & Gene Therapy, Pall Life Sciences
  • Dr Richard Snyder, Chief Scientific Officer, Brammer Bio


By registering to view this Webinar you are also signing up as a member of Cell & Gene Therapy Insights and agree to be contacted by our sponsors. We will email you a username and password so you can read all our open access content.

Dr Michael Kelly

Director, Asset Leadership, Gene Therapy, Biogen, USA

Dr Clive Glover

Senior Global Marketing Manager, Cell & Gene Therapy, Pall Corporation, UKClive Glover
Clive leads Pall’s cell and gene therapy business. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.

Dr Richard Snyder

Chief Scientific Officer, Brammer Bio., USARichard Snyder
Dr. Snyder was the founder of Florida Biologix, which was spun out of the University of Florida in 2015 and merged to create Brammer Bio in 2016. Dr. Snyder has been investigating virus biology, vector development, cGMP manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 30 years, and was a member of teams who developed novel viral vector-based human gene therapies. Dr. Snyder was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in Biology from Washington University in St. Louis.